Untitled

Franck,

doi:10.1016/1076-0512(94)00239-8

Cited by 23 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been discussed that the chronic inflammation plays a role in the malignant transformation of LP by analogy to ulcerative colitis and colorectal carcinoma [102]. Malignant transformation to squamous cell carcinoma is also described in penile, anal and vulvovaginal LP as well as in esophageal LP [90,91,103,104,105,106,107,108], as it was observed in another case at our hospital that developed an esophageal carcinoma within a chronic LP of the esophagus. With the chronic course of LP, especially in its hypertrophic variant, and an incidence of 9-26% in pediatric LP, it is very important to keep the risk of malignant transformation in mind, particularly in those patients [109,110].…”

Section: Discussionmentioning

confidence: 99%

Oral, Esophageal and Cutaneous Lichen Ruber Planus Controlled with Alitretinoin: Case Report and Review of the Literature

Kolios¹,

Maggio²,

Gubler

et al. 2013

Dermatology

View full text Add to dashboard Cite

Background: Therapy-resistant lichen planus (LP) can be a challenging condition for dermatologists. There are some case reports about successful treatments with alitretinoin of cutaneous and oral, but not of esophageal LP. Objective: We present the unique case of a patient with cutaneous, oral and esophageal LP which was refractory to classical treatment options (topical clobetasol propionate and pimecrolimus, intramuscular triamcinolone acetonide); because of systemic side effects the patient did not tolerate systemic acitretin dosed up to 25 mg daily. Methods: Oral alitretinoin was used at a dose of 30 mg daily. Results: Both oral and skin changes as well as dysphagia completely resolved within 4 weeks without any severe side effects and the drug was used for 6 months. No papules, intraoral striae or dysphagia recurred during the 6 months of treatment. After 4 months the patient relapsed with mucosal patches so that a second cycle was initiated for 6 months where oral LP lesions resolved after 4 weeks also (with sporadic mild headache). Conclusion: Further studies are needed to better understand the impact of alitretinoin in LP. Our observation suggests alitretinoin as a new, well-tolerated treatment option for esophageal LP after failed response to conventional treatments.

show abstract